United Therapeutics Corporation $UTHR Shares Sold by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,210 shares of the biotechnology company’s stock after selling 139 shares during the quarter. Greenwood Capital Associates LLC’s holdings in United Therapeutics were worth $635,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of United Therapeutics in the first quarter valued at about $313,000. Allianz Asset Management GmbH grew its stake in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after buying an additional 33,254 shares in the last quarter. LPL Financial LLC grew its stake in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after buying an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at about $227,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $434.88, for a total value of $1,739,520.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $56,534.40. This trade represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $440.00, for a total value of $440,000.00. Following the completion of the sale, the director directly owned 4,865 shares in the company, valued at approximately $2,140,600. This trade represents a 17.05% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 238,435 shares of company stock worth $93,353,482. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Up 2.2%

NASDAQ:UTHR opened at $453.07 on Friday. The business’s 50 day moving average is $356.31 and its two-hundred day moving average is $319.01. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $455.12. The company has a market cap of $20.44 billion, a PE ratio of 17.68, a P/E/G ratio of 6.76 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period last year, the business posted $5.85 EPS. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent research reports. HC Wainwright increased their target price on United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Bank of America increased their target price on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Morgan Stanley lowered their price objective on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Finally, Jefferies Financial Group raised their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Ten research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $449.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.